In vivo modeling and molecular characterization: a path toward targeted therapy of melanoma brain metastasis

Gaziel-Sovran, Avital; Osman, Iman; Hernando, Eva
May 2013
Frontiers in Oncology;May2013, Vol. 3, p1
Academic Journal
Brain metastasis (B-Met) from melanoma remains mostly incurable and the main cause of death from the disease. Early stage clinical trials and case studies show some promise for targeted therapies in the treatment of melanoma B-Met. However, the progression-free survival for currently available therapies, although significantly improved, is still very short. The development of new potent agents to eradicate melanoma B-Met relies on the elucidation of the molecular mechanisms that allow melanoma cells to reach and colonize the brain. The discovery of such mechanisms depends heavily on pre-clinical models that enable the testing of candidate factors and therapeutic agents in vivo. In this review we summarize the effects of available targeted therapies on melanoma B-Met in the clinic.We provide an overviewof existing pre-clinical models to study the disease and discuss specific molecules and mechanisms reported to modulate different aspects of melanoma B-Met and finally, by integrating both clinical and basic data, we summarize both opportunities and challenges currently presented to researchers in the field.


Related Articles

  • Modifying Clinical Trial Designs to Test Treatments for Clinical Significance in Individual Patients. Becker, R.E. // Clinical Drug Investigation;2001, Vol. 21 Issue 10, p727 

    The aim of this article was to design clinical trials that test treatments for clinical significance in individual patients. In a repeated measures design a scalar summary statistic describes the clinical course of each individual. To provide satisfactory reliability for each patient's clinical...

  • Can unequal be more fair? Ethics, subject allocation, and randomised clinical trials. Avins, Andrew L // Journal of Medical Ethics;Dec98, Vol. 24 Issue 6, p401 

    Examines several techniques for addressing the issue of randomised clinical trials. Suggestion that unbalanced randomisation may be useful for enhancing the ethical design of human experimentation; Approach to the dilemma of equipoise and randomised trials; Methodologic approaches to...

  • CNE/CME questions.  // IRB Advisor;Feb2010, Vol. 10 Issue 2, p24 

    A quiz about issues related to human experimentation in medicine is presented.

  • "Reported and actual trial deaths differ".  // BioSpectrum;Sep2012, Vol. 10 Issue 9, p18 

    The article reports that the Indian health ministry has attributed the cause of majority of reported clinical trial death cases not linked to trials.

  • Allocation bias.  // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/6/2009, Vol. 338 Issue 7707, p1395 

    A quiz about the allocation of people to treatment in clinical trials is presented.

  • Identifying barriers may improve adolescent and young adult clinical trial participation.  // Infectious Diseases in Children;Oct2009, Vol. 22 Issue 10, p54 

    The article discusses research on how identifying barriers can improve adolescent and young adult clinical trial participation, by K. Read, published in the 2009 issue of "Pediatrics."

  • Should There Be Regulatory Oversight of Clinical Trial Web Sites? Ehrenberger, Heidi E. // ONS News;Sep2002, Vol. 17 Issue 9, p1 

    Focuses on the oversight strategies used to accelerate the recruitment of participants in clinical trials. Pressures on industry-sponsored clinical research according to a report by the U.S. Office of the Inspector General; Use of Web sites in recruiting participants; Information concerning...

  • St. Thomas Heart Performs New Heart Valve Procedure.  // Tennessee Tribune;11/29/2012, Vol. 23 Issue 48, p6B 

    The article reports that a team of cardiologists and cardiovascular surgeons with Saint Thomas Heart at Saint Thomas Hospital are the first in the state to perform the first successful transcatheter aortic valve replacement (TAVR) via the transapical approach on patients not part of a clinical...

  • Surrogate end points in clinical trials: Are we being misled? Fleming, Thomas R.; DeMets, David L. // Annals of Internal Medicine;10/01/96, Vol. 125 Issue 7, p605 

    Assesses the validity of using surrogate end points in phase 3 clinical trials. Goal of phase 3 trial; Requirements for surrogate end points; Arrhythmia suppression; Exercise tolerance in congestive heart failure; Tumor response; Inability of surrogate end points to predict true clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics